TELA Bio Stock

TELA Bio FCF Yield

The Free Cash Flow Yield of TELA Bio (TELA) as of Aug 7, 2026 is -85.83 %. In the previous year, Free Cash Flow Yield was -127.51 % — a change of -32.68% (higher).

FCF Yield

-85.83 %

YoY

-32.68%

Last updated:

Free Cash Flow Yield of TELA Bio is 2026 -85.83 % . Free Cash Flow Yield of TELA Bio was 2025 -127.51 % . It decreases by -32.68% higher compared to the previous year.
Access this data via the Eulerpool API

TELA Bio Stock analysis

What does TELA Bio do? TELA Bio Inc is an American medical technology company that specializes in the development and manufacture of innovative surgical implants. The history of this company began in 2012 when a group of experienced bioengineers and medical professionals decided to develop a better surgical tissue replacement material. The idea was to create a product that not only supports the healing process but is also safe, durable, and easy to handle. Over the years, TELA Bio has successfully implemented the business model of complete vertical integration, which means that the company takes care of everything from research and development to production, distribution, and marketing of its products. This allows the company to build closer relationships with its customers and improve the quality of its products by addressing the needs and requirements of its users. The core business of TELA Bio focuses on a wide range of surgical tissue replacement materials specifically designed for plastic and reconstructive surgery, hernia repair, and wound healing. These products are characterized by their high biocompatibility, strength, and flexibility, and provide a safe and effective solution for a variety of medical applications. Key products offered by TELA Bio include the OviTex® product family, which includes surgical mesh materials for supporting wound healing in hernia repairs and abdominal surgeries, as well as tissue replacement materials for breast reconstruction after mastectomy. These products are known for their high biocompatibility and ability to integrate into the surrounding tissue and restore natural tissue structures. In addition, TELA Bio also offers the TELADERM®-DH product, specifically developed for wound healing in diabetes patients. This product consists of a tissue replacement material that supports skin repair and reduces the risk of infection, particularly in patients with poorly healing wounds. Overall, TELA Bio has developed a wide range of products tailored to the needs of modern medicine. The company is focused on improving the quality of medical care and providing innovative solutions for surgical wound healing. With its successful implementations in research, production, and distribution, TELA Bio is well-positioned to continue growing and solidify its position as a leading provider of medical implants. TELA Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TELA Bio stock

Free Cash Flow Yield of TELA Bio is -85.83 % in 2026.

Free Cash Flow Yield of TELA Bio changed from -127.51 % to -85.83 %, representing a -32.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield TELA Bio since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's TELA Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — TELA Bio

All Key Metrics — TELA Bio